Tango Therapeutics
TNGX
92 hedge funds and large institutions have $276M invested in Tango Therapeutics in 2023 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 25 increasing their positions, 23 reducing their positions, and 8 closing their positions.
125% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 8
12% more funds holding
Funds holding: 82 → 92 (+10)
1.22% more ownership
Funds ownership: 77.96% → 79.18% (+1.2%)
9% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 23
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
45% less capital invested
Capital invested by funds: $498M → $276M (-$223M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Casdin Capital
New York
|
+$5.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.47M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.16M |
| 4 |
Millennium Management
New York
|
+$981K |
| 5 |
Squarepoint
New York
|
+$538K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
-$2.1M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$1.96M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.12M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$1.1M |
| 5 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
-$848K |
TNGX Hedge Fund Activity: Q1 2023 in Review
92 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Tango Therapeutics (TNGX) for Q1 2023, worth a combined $276M — down 45% from $498M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new TNGX positions and 8 closed out — a net gain of 10 holders — while 25 added to existing stakes and 23 trimmed.
The largest buyer was Casdin Capital, opening a new position worth an estimated $5.8M. The largest seller was Walleye Capital, exiting entirely with an estimated $2.1M sold.
- 92 institutional investors held Tango Therapeutics (TNGX) as of Q1 2023, up from 82 in Q4 2022.
- Funds reported $276M of Tango Therapeutics stock for Q1 2023, down 45% quarter-over-quarter.
- 18 funds opened new Tango Therapeutics positions in Q1 2023 and 8 closed out, a net change of +10 holders.
- The largest Tango Therapeutics buyer in Q1 2023 was Casdin Capital, an estimated $5.8M added.
- The largest Tango Therapeutics seller in Q1 2023 was Walleye Capital, an estimated $2.1M sold.
Based on aggregated 13F filings for Q1 2023.